BOULDER, Colo.--(BUSINESS WIRE)--Dec. 23, 2013--
Clovis Oncology (NASDAQ:CLVS) announced today that an abstract
discussing the findings of the ongoing Phase I portion of the Phase I/II
clinical study of CO-1686 has been accepted for Proffered Paper (Oral)
presentation during the 4thEuropean Lung Cancer Conference
(ELCC). CO-1686 is the Company’s novel, oral, targeted covalent
(irreversible) inhibitor of mutant forms of the epidermal growth factor
receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC)
in patients with initial activating EGFR mutations as well as the
dominant resistance mutation T790M. The conference takes place March
26-29, 2014 in Geneva, Switzerland.
This oral presentation will be the next update of clinical data from the
Phase I/II study of CO-1686. The Company intends to describe its
clinical development plan for CO-1686 at the JP Morgan Healthcare
Conference in mid-January and at the Clovis Oncology R&D Day for
Investors and Analysts to be held on January 27.
The abstract accepted for Proffered Paper (Oral) presentation is titled
“First-in-Human Evaluation of CO-1686, an Irreversible, Highly Selective
Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M).”
Data contained in the ELCC abstract, which will be published in
mid-March, was current as of the submission deadline of December 9,
2013. Data to be presented in the oral session will include more current
data from the trial.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops diagnostic tools that direct a
compound in development to the population that is most likely to benefit
from its use. Clovis Oncology is headquartered in Boulder, Colorado.
To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve substantial risks and uncertainties
that could cause our clinical development programs, future results,
performance or achievements to differ significantly from those expressed
or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in the
initiation of future clinical trials, availability of data from ongoing
clinical trials, expectations for regulatory approvals, and other
matters that could affect the availability or commercial potential of
our drug candidates. Clovis Oncology undertakes no obligation to update
or revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well as
risks relating to the business of the company in general, see Clovis
Oncology’s Annual Report on Form 10-K for the year ended December 31,
2012 and its other reports filed with the Securities and Exchange
Commission.
Source: Clovis Oncology, Inc.
Clovis Oncology
Anna Sussman, 303-625-5022
asussman@clovisoncology.com
or
Breanna
Burkart, 303-625-5023
bburkart@clovisoncology.com